Company profile
Agentix Corp.
OTC: AGTX · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
17DFH 1DQ 33GM 26SS 28
v0.1 · 65/100 weight · provisional
↑ growth stability, listing tenure · ↓ revenue growth (YoY), return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$485.6k
Employees
2
as of 2026-08-26
Market cap
$801.3k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$485.6k-$485.6k2026
Operating income-$445.2k-$445.2k2026
Total assets$771$7712026
Liabilities$3.6M$3.6M2026
Equity-$3.6M-$3.6M2026
Revenue trend
FY2015 – FY2023 · USD
FY15
FY16
FY17
FY20
FY22
FY21
FY23
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Agentix Corp.’s revenue?
Agentix Corp. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Avalon GloboCare Corp.35DGenix Pharmaceuticals Corporation——Pharmadrug Inc.——NKGen Biotech, Inc.——ChitogenX Inc.——Hepion Pharmaceuticals, Inc.24DNeighbors
Orange →Key facts
CEORiazul Huda
SectorHealthcare
IndustryBiotechnology
HeadquartersDana Point, CA
ExchangeOTC: AGTX
Employees2
IPO date2015-08-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.